NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) is set to participate in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, scheduled for September 9-10 in New York City. The company will use the event to highlight its exosome-based therapeutic platform, development pipeline, and U.S. manufacturing and commercialization initiatives as it advances preclinical programs and prepares for potential clinical development.
Yoram Drucker, co-founder and chairman of NurExone, is scheduled to present to investors and conduct one-on-one meetings during the conference. The presentation will focus on the company's lead candidate, ExoPTEN, which has demonstrated strong preclinical potential in treating acute spinal cord and optic nerve damage. Additionally, NurExone aims to supply quality exosomes and minimally invasive targeted delivery systems, anchoring its North American strategy through its Exo-Top platform.
The company's participation in this conference is a critical step in gaining visibility among investors and industry stakeholders, particularly as it prepares for regulatory milestones. The U.S. initiatives are part of a broader effort to establish a manufacturing presence and commercialize its therapies in the North American market.
NurExone's exosome-based approach represents a novel therapeutic modality for central nervous system injuries, which currently have limited treatment options. The potential of ExoPTEN to promote regeneration in spinal cord and optic nerve injuries addresses a significant unmet medical need. The company's strategy includes not only developing its own product candidates but also positioning itself as a supplier of high-quality exosomes and delivery systems for other companies in the regenerative medicine space.
The conference appearance comes at a time when the exosome therapy field is gaining traction, with increasing investment and research interest. By showcasing its platform and pipeline, NurExone aims to attract potential partners and investors to support its clinical development and commercialization efforts.
For more details on the conference presentation, interested parties can view the full press release via this link.
